Anti-RANKL Inhibits Thymic Function and Causes DRONJ in Mice

BACKGROUND: Denosumab, a human monoclonal antibody against receptor activator of nuclear factor-kappa B ligand (RANKL), is a novel bone antiresorptive agent used in patients with osteoporosis or metastatic bone cancer. Denosumab-related osteonecrosis of the jaw (DRONJ) has been recently reported in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Yusuke, Kikuiri, Takashi, Sugiyama, Takahiro, Maeda, Ayako, Izumiyama, Daisuke, Yahata, Daigo, Yoshimura, Yoshitaka, Shirakawa, Tetsuo, Kitagawa, Yoshimasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033356/
https://www.ncbi.nlm.nih.gov/pubmed/35464103
http://dx.doi.org/10.1155/2022/9299602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033356/
https://www.ncbi.nlm.nih.gov/pubmed/35464103
http://dx.doi.org/10.1155/2022/9299602

Ejemplares similares